Alessandro P Delitala1, Antonio Terracciano2, Edoardo Fiorillo3, Valeria Orrù4, David Schlessinger5, Francesco Cucca6. 1. Azienda Ospedaliero-Universitaria di Sassari, Via Michele Coppino 26a, Sassari 07100, Italy. Electronic address: aledelitala@tiscali.it. 2. Department of Geriatrics, Florida State University College of Medicine, 1115 W. Call Street, Tallahassee, FL 32306, USA. Electronic address: antonio.terracciano@med.fsu.edu. 3. Istituto di Ricerca Genetica e Biomedica (IRGB), Consiglio Nazionale delle Ricerche, c/o Cittadella Universitaria di Monserrato, Cagliari, Italy. Electronic address: edoardofiorillo@gmail.com. 4. Istituto di Ricerca Genetica e Biomedica (IRGB), Consiglio Nazionale delle Ricerche, c/o Cittadella Universitaria di Monserrato, Cagliari, Italy. Electronic address: v.orru@tiscali.it. 5. National Institute on Aging, NIH, DHHS, Baltimore, MD, USA. Electronic address: SchlessingerD@grc.nia.nih.gov. 6. Istituto di Ricerca Genetica e Biomedica (IRGB), Consiglio Nazionale delle Ricerche, c/o Cittadella Universitaria di Monserrato, Cagliari, Italy; Department of Biomedical Sciences, Azienda Ospedaliero-Universitaria di Sassari, Sassari, Italy. Electronic address: francesco.cucca@irgb.cnr.it.
Abstract
OBJECTIVE: To evaluate the association between depressive symptoms and thyroid autoimmunity, and the effect of thyroid hormone on the risk of depression. METHODS: We included 3138 individuals from SardiNIA project, none of whom was taking thyroid medication and antidepressants. Thyrotropin (TSH), free thyroxine (FT4), and antibodies against thyroperoxidase (TPOAb) were measured in all the sample. Depressive symptoms were assessed with Center for Epidemiologic Studies Depression Scale (CES-D). RESULTS: We found no association between TPOAb and depressive symptoms and no linear association between TSH or FT4 levels and depressive symptoms. However, individuals in the lowest and highest FT4 quintiles showed a higher CES-D score compared to individuals in the middle quintile. In addition, participants in the lowest and highest FT4 quintiles had an increased risk of CES-D≥16 with odds ratios of 1.44 (95% CI=1.09-1.89) and 1.33 (95% CI=1.01-1.77), respectively. LIMITATIONS: Cross-sectional design of the study. CONCLUSIONS: A U-shaped relation was found between FT4 and depressive symptoms: compared to average FT4 values, both high and low thyroid function was associated with more depressive symptoms. Further studies are necessary to determine the exact cause-effect relation of this association.
OBJECTIVE: To evaluate the association between depressive symptoms and thyroid autoimmunity, and the effect of thyroid hormone on the risk of depression. METHODS: We included 3138 individuals from SardiNIA project, none of whom was taking thyroid medication and antidepressants. Thyrotropin (TSH), free thyroxine (FT4), and antibodies against thyroperoxidase (TPOAb) were measured in all the sample. Depressive symptoms were assessed with Center for Epidemiologic Studies Depression Scale (CES-D). RESULTS: We found no association between TPOAb and depressive symptoms and no linear association between TSH or FT4 levels and depressive symptoms. However, individuals in the lowest and highest FT4 quintiles showed a higher CES-D score compared to individuals in the middle quintile. In addition, participants in the lowest and highest FT4 quintiles had an increased risk of CES-D≥16 with odds ratios of 1.44 (95% CI=1.09-1.89) and 1.33 (95% CI=1.01-1.77), respectively. LIMITATIONS: Cross-sectional design of the study. CONCLUSIONS: A U-shaped relation was found between FT4 and depressive symptoms: compared to average FT4 values, both high and low thyroid function was associated with more depressive symptoms. Further studies are necessary to determine the exact cause-effect relation of this association.
Authors: Katrine Fjaellegaard; Jan Kvetny; Peter N Allerup; Per Bech; Christina Ellervik Journal: Nord J Psychiatry Date: 2014-07-01 Impact factor: 2.202
Authors: Alessandro P Delitala; Maristella Steri; Edoardo Fiorillo; Michele Marongiu; Edward G Lakatta; David Schlessinger; Francesco Cucca Journal: Cytokine Date: 2018-08-30 Impact factor: 3.861
Authors: Alessandro P Delitala; Angelo Scuteri; Edoardo Fiorillo; Valeria Orrù; Edward G Lakatta; David Schlessinger; Francesco Cucca Journal: J Clin Med Date: 2021-01-22 Impact factor: 4.241
Authors: Benjamín Romero-Gómez; Paula Guerrero-Alonso; Juan Manuel Carmona-Torres; Blanca Notario-Pacheco; Ana Isabel Cobo-Cuenca Journal: Int J Environ Res Public Health Date: 2019-11-28 Impact factor: 3.390